In a pharmaceutical company, quality is not an add-on to manufacturing, it is a condition for putting a product on the market. The trouble is that in many organisations it still lives in binders, Excel sheets and email inboxes, and quality processes rely on the memory of specific people. In a regulated environment that no longer holds up: the regulator expects consistent data, a complete audit trail and repeatable processes, not a reconstruction of events from scattered notes.
In our experience, the hard part is not the tool itself but connecting quality requirements to the company’s real processes and doing it so it survives an audit. We do not have a finished eQMS rollout to show as a case study, but we have something just as important: people and skills from projects in regulated pharma environments, whom we place as team augmentation or a dedicated team.
Why is paper-based, scattered quality not enough in a regulated environment?
Because every gap in data consistency becomes a compliance risk, not just an inconvenience:
- documents exist in many versions, and no one is sure which one is current,
- deviations and CAPAs get lost in email, so deadlines stop being tracked,
- training and SOPs drift apart from what people actually do,
- audit preparation takes weeks, because evidence has to be gathered by hand,
- there is no audit trail, so you cannot reconstruct who changed what and when.
As a result the organisation pays twice: in people’s time and in the risk of findings from the regulator.
What is an eQMS and what should it cover?
An eQMS, an electronic quality management system for pharma, turns scattered processes into one controlled environment. A well-structured one covers:
- document management and a controlled workflow (versioning, reviews, approvals),
- deviations and CAPA with a full event lifecycle,
- change control,
- SOPs and training records tied to roles,
- audits, complaints and supplier management,
- the audit trail and electronic signature as a cross-cutting layer.
The key is for these modules to work together rather than sit as separate islands, so we design an eQMS as a coherent process, not a pile of forms.
How do you digitise deviations and CAPA?
Deviations and CAPA are the heart of a quality system, because they show whether the organisation learns from its mistakes. We build this area to lead the user by the hand:
- deviation logging with risk classification and immediate action,
- root cause analysis as a mandatory step,
- a corrective and preventive action plan with owners and deadlines,
- effectiveness verification of the CAPA instead of merely “closing the ticket”,
- automatic reminders and escalations as a deadline approaches.
That way CAPA stops being a formality and becomes a real quality control mechanism with hard data for the audit.
How do you structure change control?
In pharma, a change can cost more than the problem itself if it is not controlled. So we model change control as a process with clear gates:
- a change request with an impact assessment on product, process and validation,
- a risk assessment and the approvals required before implementation,
- links from the change to the documents, SOPs and training it affects,
- implementation tracking and a formal closure with evidence.
We tie change control to the other modules so that a single change automatically triggers updates to the related documents and training.
How do you run SOPs and training records in one system?
A procedure no one has read protects against nothing. So we connect documentation with people’s competencies:
- SOPs in a controlled workflow, with a current version and a change history,
- automatic training assignment once a new SOP version is published,
- a training record tied to role and position,
- task access blocked until the required training is confirmed.
This setup means aligning training with procedures stops being a separate project before every audit.
How do you ensure an audit trail and electronic signature (Part 11-type requirements)?
In a regulated environment this layer is non-negotiable. The audit trail and electronic signature must be built into the system, not bolted on at the end. Frameworks such as GxP, 21 CFR Part 11 and GAMP describe what is expected, and we treat them as a reference point, not as a ready-made rollout of ours:
- an immutable audit trail recording who changed what, when and why,
- an electronic signature with unambiguous identity and action context,
- role-based access control and segregation of duties,
- a validation approach (in the spirit of GAMP, for example) so the system is defensible at audit.
We design these mechanisms from the start, because retrofitting them later is usually more expensive and riskier than doing it right away.
How do you integrate an eQMS with the rest of your systems?
An eQMS rarely stands alone. For quality data to be trustworthy, we connect it to its surroundings:
- integration with ERP (batch release, material data, for example),
- a link to MES and LIMS, where quality touches production and the lab,
- identity management (SSO, user directory) consistent with the rest of the company,
- quality reporting and metrics fed from multiple sources.
We look at this end to end, because the value appears only when data is not rekeyed by hand between systems.
Which skills do we provide for an eQMS project?
We shape the team around the specific project stage, not “just in case”. To digitise quality in pharma we most often staff:
- a solution architect who understands regulated environments and validation,
- backend and frontend developers building eQMS modules or platform extensions,
- integration specialists connecting the eQMS to ERP, MES and LIMS,
- quality engineers and DevOps owning environments, releases and validation documentation.
Our engineers have worked on projects in the regulated pharma world, so they understand that code is only part of the delivery, and the rest is evidence, documentation and repeatability.
Is it worth adding an AI layer to an eQMS?
Optionally yes, as long as AI supports decisions rather than making them in place of a human. In quality we see sensible applications:
- root cause analysis supported by models trained on deviation data,
- trend detection and recurring issues across a backlog of tickets,
- search across documentation (RAG) instead of manually scanning SOPs,
- initial classification of deviations and complaints for faster handling.
Our AI and Data competence is real (within the RITS Group we have delivered GenAI, RAG and LLM projects), but we treat it as a layer added deliberately, keeping validation and human oversight in place.
How do we do it at RITS?
We do it as a nearshore partner from Poland, with experience in regulated-environment projects:
- we staff the roles needed to digitise quality, from the architect to integrations,
- we design the eQMS as a process, not a pile of forms, with the audit trail and e-signature from the start,
- we treat GxP, Part 11 and GAMP as a reference point for the project and validation,
- we verify skills before the start and shape the team around the stage and the company’s specifics.
Most often we do this as custom software built by our team and, where skills need topping up fast, as team augmentation.
Where to start with digitising quality and compliance?
Start from the single most painful process (usually deviations and CAPA, or document control) and from the question of which audit trail you have to prove. That defines the eQMS scope, the validation requirements and the roles you need. We covered the differences between engagement models in our article on IT engagement models.
Digitising quality and compliance in pharma? Let’s talk - we’ll match a team and an approach to your processes and your regulator’s requirements.